Has telemedicine made medical cannabis treatment more accessible in Germany, or has the rapid growth of online prescribing created new risks for patients?
The question will be debated at the Cannabis Health Symposium in Frankfurt on Wednesday, with speakers examining how online consultations can serve patients safely.
Bertan Türemis, a neurobiologist specialising in medical cannabis and CEO of bemedica, a consultancy advising cannabis manufacturers and pharmacies, will join the panel Telemedicine Debate: Revolution or Risk for Medical Cannabis.
The discussion will examine when remote consultations are appropriate, what safeguards patients need and how proposed restrictions on postal deliveries could affect their treatment.
He will be joined by Dr Christiane Neubaur, managing director of the cannabis pharmacies association VCA; Tobias Bosse, chief commercial officer at Grünhorn Group; and Dr Julian Wichmann, CEO of Bloomwell.
The debate comes as Germany considers further restrictions on remote prescribing and mail-order dispensing — proposals explored in Cannabis Health’s recent explainer on telemedicine in Germany.
Mr Türemis has eight years’ experience across pharmaceuticals, medical devices and diagnostics, including medical affairs roles at Synbiotic Sales, Fette Pharma and Sanity Group. He also founded mechoulam.de, a free platform summarising cannabis research for prescribing physicians.
The panel begins at 10.20am local time.
The Cannabis Health Symposium takes place at Mainhaus, Frankfurt, on 4 November. View the programme and secure your place here.
